Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer

Abstract excerpt

KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS(G12V) into human embryonic kidney 293 and MRC5...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biochemical and Molecular Research
• Share to Cholangiocarcinoma and Gallbladder Cancer Studies
• Share to Colorectal Cancer Treatments and Studies